An intermediate dose of LCMV clone 13 causes prolonged morbidity that is maintained by CD4+ T cells.
about
The central role of hypothalamic inflammation in the acute illness response and cachexiaCD8+ T cell-derived IFN-γ prevents infection by a second heterologous virus.NK cells controlling virus-specific T cells: Rheostats for acute vs. persistent infections.CD4 T cell responses in latent and chronic viral infections.A distinct brain pathway links viral RNA exposure to sickness behaviorGenetic disruption of CD8+ Treg activity enhances the immune response to viral infectionType I interferons regulate susceptibility to inflammation-induced preterm birth.Regulation of CD4 T cells and their effects on immunopathological inflammation following viral infection.Dose of Retroviral Infection Determines Induction of Antiviral NK Cell Responses.The microRNA miR-31 inhibits CD8+ T cell function in chronic viral infection.Increased Immune Response Variability during Simultaneous Viral Coinfection Leads to Unpredictability in CD8 T Cell Immunity and Pathogenesis.Clonal exhaustion as a mechanism to protect against severe immunopathology and death from an overwhelming CD8 T cell response.Tim-3 co-stimulation promotes short-lived effector T cells, restricts memory precursors, and is dispensable for T cell exhaustion.
P2860
Q28080648-56C84E10-2CB6-4804-B305-0241ADB9A1A3Q36456970-448140E5-85C7-490A-829C-AB57EE04E055Q36464528-50D8BD1A-8C4C-4CD0-8C60-BA5862C16591Q36837631-B68C9F3C-893F-4B89-9169-6628BAAAB967Q37110979-8C612EA0-4615-4D50-B078-604ABE7CB122Q37421220-B2806771-08E3-47DA-923D-0089055D29ADQ37677428-78A87719-5F68-46DA-82D7-7219C886ADFDQ38743043-1711F128-F10A-4D0E-8974-109A255C62FDQ40042449-E896F68A-97D6-47CA-8229-8A9C8C6A3E55Q40191149-94DDF241-5E0B-4BC2-B1A6-CBD56332A2D7Q41055245-33968FA8-B35A-4EF8-BD81-41507D4852EFQ42245118-CA70B1D5-8E35-42D0-8400-2BDEFE24FE8DQ49790513-28F5F8A0-6D33-4674-9A02-787D91224DA4
P2860
An intermediate dose of LCMV clone 13 causes prolonged morbidity that is maintained by CD4+ T cells.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
An intermediate dose of LCMV c ...... is maintained by CD4+ T cells.
@ast
An intermediate dose of LCMV c ...... is maintained by CD4+ T cells.
@en
type
label
An intermediate dose of LCMV c ...... is maintained by CD4+ T cells.
@ast
An intermediate dose of LCMV c ...... is maintained by CD4+ T cells.
@en
prefLabel
An intermediate dose of LCMV c ...... is maintained by CD4+ T cells.
@ast
An intermediate dose of LCMV c ...... is maintained by CD4+ T cells.
@en
P2093
P2860
P1433
P1476
An intermediate dose of LCMV c ...... is maintained by CD4+ T cells.
@en
P2093
Andrew Stamm
Laura Valentine
Mary Premenko-Lanier
Rashaun Potts
P2860
P304
P356
10.1016/J.VIROL.2012.01.005
P407
P577
2012-02-04T00:00:00Z